Avior Wealth Management LLC Reduces Stake in Ascendis Pharma A/S (NASDAQ:ASND)

Avior Wealth Management LLC lowered its holdings in Ascendis Pharma A/S (NASDAQ:ASND) by 7.9% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 7,561 shares of the biotechnology company’s stock after selling 651 shares during the period. Avior Wealth Management LLC’s holdings in Ascendis Pharma A/S were worth $1,041,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. SG Americas Securities LLC lifted its stake in shares of Ascendis Pharma A/S by 410.4% in the 4th quarter. SG Americas Securities LLC now owns 33,944 shares of the biotechnology company’s stock valued at $4,673,000 after purchasing an additional 27,293 shares during the period. ARS Investment Partners LLC lifted its stake in shares of Ascendis Pharma A/S by 0.9% in the 4th quarter. ARS Investment Partners LLC now owns 265,480 shares of the biotechnology company’s stock valued at $36,549,000 after purchasing an additional 2,369 shares during the period. Crossmark Global Holdings Inc. lifted its stake in shares of Ascendis Pharma A/S by 28.5% in the 4th quarter. Crossmark Global Holdings Inc. now owns 10,435 shares of the biotechnology company’s stock valued at $1,436,000 after purchasing an additional 2,315 shares during the period. Diversified Trust Co lifted its stake in shares of Ascendis Pharma A/S by 7.4% in the 4th quarter. Diversified Trust Co now owns 45,038 shares of the biotechnology company’s stock valued at $6,200,000 after purchasing an additional 3,114 shares during the period. Finally, GAMMA Investing LLC lifted its stake in shares of Ascendis Pharma A/S by 58.0% in the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 214 shares during the period.

Wall Street Analysts Forecast Growth

ASND has been the subject of a number of research analyst reports. Cantor Fitzgerald restated an “overweight” rating and issued a $170.00 target price on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. TD Cowen reduced their price objective on Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Oppenheimer reduced their target price on Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating for the company in a report on Friday, November 15th. StockNews.com raised Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Finally, Stifel Nicolaus lifted their price objective on Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a “buy” rating in a report on Friday, November 15th. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $192.07.

Ascendis Pharma A/S Stock Performance

NASDAQ ASND opened at $128.20 on Friday. The company has a market capitalization of $7.78 billion, a PE ratio of -15.87 and a beta of 0.65. The business’s fifty day moving average is $133.28 and its 200 day moving average is $133.25. Ascendis Pharma A/S has a fifty-two week low of $111.09 and a fifty-two week high of $161.00.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.